Hong Kong Book Fair, Sports and Leisure Expo and World of Snacks open today

HKTDC’s Book Fair, Sports and Leisure Expo and World of Snacks have attracted 760 exhibitors to participate in the seven-day events
The Book Fair’s theme this year is Film and Television Literature. Renowned writers such as Jin Yucheng, author of Blossoms, and Yuyi, author of City of Darkness, will share their creative journey
The World of Art & Culture showcases works from 31 countries and regions, including AI-powered interactive installations
The Sports and Leisure Expo offers a check-in spot for cheering on Hong Kong’s Olympic athletes while the World of Snacks gathers more than 1,200 snacks from across the globe
Entry before noon costs HK$10 with an Octopus card, and full price ticket holders who enter on the first two days can enjoy free re-entry at certain time slots. Children aged 0-3 and adults aged 65 or above will be admitted free of charge

HONG KONG, July 18, 2024 – (ACN Newswire) – 17 July 2024 – The 34th HKTDC Hong Kong Book Fair, 7th HKTDC Sports and Leisure Expo and 4th HKTDC World of Snacks all commence today, running for seven days (17 to 23 July) at the Hong Kong Convention and Exhibition Centre (HKCEC). Organised by the Hong Kong Trade Development Council (HKTDC), the three summer cultural and leisure events offer a diverse range of activities that cater for the whole family. The opening ceremony for the fairs took place this morning, officiated by Raistlin Lau, Under Secretary for Culture, Sports and Tourism of the Hong Kong Special Administrative Region (HKSAR) Government, and accompanied by Margaret Fong, HKTDC Executive Director.

Speaking at the opening ceremony, Ms Fong said: “The HKTDC is committed to promoting Hong Kong’s business development and injecting vitality into the Hong Kong economy through organising mega events such as these, solidifying the city’s reputation as the events capital of Asia. This year’s Book Fair, Sports and Leisure Expo and World of Snacks have attracted 760 exhibitors, providing an important promotional and business platform for different industries while allowing visitors to enjoy diverse activities spanning reading, sports, leisure, and snack shopping. This year’s Book Fair, an annual summer cultural event in Hong Kong, will stage more than 600 cultural activities on-site and off-site, inviting over 250 prominent Chinese and foreign-language writers and celebrities to host seminars, promoting literary exchange and connecting book lovers through literature.”

The Book Fair continues to receive funding from the HKSAR Government’s Cultural and Creative Industries Development Agency to support featured activities, including the World of Art & Culture, the International Publishing Forum and the debut of the IP Roundtable.

Theme of the year seminar series delves into film and TV literature

This year’s Book Fair, with the theme Film and Television Literature and the tagline “Reading the World: Storytelling from Page to Screen”, focuses on featured writers such as Erica Li, Raymond To, Joyce Chan, Norris Wong, Chiang Hiu Mei and Law Kar. The Art Gallery features two other exhibition zones, namely Featured Directors and Classic Literary Adaptations, introducing selected works by renowned filmmakers such as Wong Kar-wai, Ho Cheuk-tin, Nick Cheuk, Tsui Hark, Ann Hui and Stanley Kwan, as well as paying tribute to literary masters like Yi Shu, Lilian Lee, Jin Yong, Ni Kuang and Eileen Chang.

Featured writers of the year and featured directors are invited to explore the intersection of film, television and literature through the Theme of the Year Seminar Series. Earlier today, Raymond To kicked off the series with his talk on “Transforming Texts into Lines and Dialogues”, while renowned director Stanley Kwan will share his unique perspectives on women, film and literary adaptations on 20 July.

World of Art & Culture promotes cultural exchange

The World of Art & Culture provides booklovers with a multifaceted understanding of literature in film and television from 31 countries and regions. In addition to works from Mainland China, Hong Kong and Taiwan, it also presents pieces from Argentina, Colombia, the Czech Republic, France, Indonesia, Korea, Mexico, Peru, the Philippines, Spain, Switzerland, Vietnam and more. This year, the World of Art & Culture features two interactive installations. Trailing the Scenes showcases Hong Kong film shooting locations and related literary works on an interactive map, allowing visitors to download relevant images, while the Shifting the Scripts by AI installation enables visitors to input keywords to re-compose classic film scenes using AI, allowing them to experience the creative process.

Furthermore, the World of Art & Culture features a miniature of the Kowloon Walled City. Yuyi, author of the novel City of Darkness that was adapted into the hit film Twilight of the Warriors: Walled In, will join the Book Fair in person and host a seminar titled “City of Darkness – From Novel to Film” to share his creative journey.

This year, the Mainland China Publishers Zone at the Book Fair is highlighting Beijing as the thematic city, with the theme Beijing and Hong Kong Weave Dreams Together – Painting a Vibrant Chapter through Literary Splendour. The zone will showcase books and creative products which embody historical and cultural characteristics of Beijing, demonstrating the charm of the nation’s capital through the achievements of its modern development.

Cultivating a reading culture through acclaimed writers

The Book Fair continues to feature the Eight Seminar Series, with authors invited to share and exchange ideas on topics including Renowned Writers, English and International Reading, World of Knowledge, Children and Youth Reading, Hong Kong Cultural and Historical, Lifestyle and Personal Development and Spiritual Growth, in addition to the Theme of the Year series. The Renowned Writers Seminar Series, co-organised with Ming Pao and Yazhou Zhoukan, has invited renowned Chinese-language authors from the mainland, Taiwan and Hong Kong to share their creative insights. On 20 July, Jin Yucheng, author of the novel that was adapted into the TV drama Blossoms, will delve into the charismatic Shanghai depicted in his creation. Pioneer of Chinese avant-garde fiction Su Tong will share his creative journey on the same day in a talk titled “The Intersecting Paths of Literature”. Other featured authors include Mao Jian, Zhu Tianyi, Shum Sai-shing, Ng See-yuen, Perry Lam, Ban Yu, Xu Zidong, Chen Chongzheng, Jiao Tong, Shan Weijian, Qiao Ye, Huang Deng, Ge Liang, Lei Chien, Cai Chongda and Ian Huen.

The English and International Reading Seminar Series continues to welcome leading English-language authors from around the world. Today (17 July), British scholar Christopher Cowell, who examines the relationship between architecture and urban cultural history, will discuss urban development in Hong Kong from 1841 to 1849. Tomorrow (18 July), renowned Czech illustrator and animator Galina Miklínová will take the audience into the world of animation and introduce the Oddsockeaters. The Story Sharing by Celebrities session has invited CUHK Medical School Associate Dean Dr Teoh Yuen-chun, renowned pianist Lee Ka-ling and Ngong Ping 360 Managing Director Tung Pui-chuen to offer meaningful parent-child activities. For more details on the seminars and the line-up of speakers, please visit: https://hkbookfair.hktdc.com/en/Events/Event-Schedule.html

Sports and Leisure Expo celebrates Olympic spirit

The quadrennial Olympic Games will kick off in Paris next week, and the public can get a head start on the electric atmosphere at the Sports and Leisure Expo. The event has invited star athletes to join sharing sessions, including Hong Kong Men’s Rugby Sevens representative Yiu Kam-shing, former Hong Kong Karatedo and Athletics representative Tong Cheuk-pan, and local ice hockey player Cheung Tsz-ching (who appeared in the TV drama Sparks), to share their ups and downs. The Hong Kong Sports Institute (Booth 5C-C02) has set up an instant photo booth encouraging the public to take pictures with props, which will be used to create a mosaic photo wall to show their support for Hong Kong athletes competing in the Olympics.

The Hong Kong Playground Association (Booth 5C-D02) has introduced a new parent-child zipline experience in the Sports Hub zone this year. Under the guidance of instructors, participants can navigate through various obstacles and glide along a 15-metre-long zipline to enjoy an exhilarating ride.

Maintaining health becomes much easier with technology. Hanlun GeronTech Limited’s (Booth 5C-B25) Tai Chi Robot was designed to cater for the elderly. It simulates the moves of an experienced tai chi master, helping seniors to train their muscles and prevent falls. Additionally, former Hong Kong triathlete Szeto Shiu-yan will share how she uses sports data to analyse her performance and plan her daily training.

The perennially popular Japan Pavilion has expanded once again to reach its biggest scale since the pandemic. The World Expo 2025 Osaka, Kansai (Booth 5B-E11) is participating this year, introducing the expo theme, “Designing Future Society for Our Lives”, to visitors. The Japan National Tourism Organization (Booth 5B-D02) is teaming up with 18 Japanese prefectures to showcase the rich traditional culture of Japan, with Hokkaido Prefecture (Booth 5B-E02) introducing its latest travel information via virtual reality experiences and photo spots. The Ainu Indigenous Culture Experience zone highlights the Upopoy National Ainu Museum and Park.

The Sports and Leisure Expo is hosting nearly 60 exciting events and performances, including a local illustrator sharing session, an introduction to emerging musical instruments, a Speed Stacks Tournament and a Rhythmic Gymnastics Dance Performance, blending thrills, education and entertainment for the benefits of visitors.

World of Snacks offers comprehensive insights into global treats

This year’s World of Snacks has brought together more than 1,200 different snacks, divided into six zones – Travel Delights, Chocolate and Sweet Factory, Oldie Snacks, Yummy & Healthy, Party Time and Snack Bar – to present visitors with a variety of classic flavours, healthy options and taste sensations from across the globe.

Making its debut at the event, Nestlé (Booth 5B-B02) has launched new ice cream flavours and is offering special promotions, including a buy-one-get-one-free offer on ice cream cups or scoops, redeemable with any purchase receipt from the Book Fair or Sports and Leisure Expo. Additionally, a series of snack-related activities are being organised for visitors, such as the Natural Honey and Sesame Cake Making workshop and Mindfulness Coffee workshop.

Tickets for the Hong Kong Book Fair, Sports and Leisure Expo and World of Snacks can be purchased through e-payment sponsor BoC Pay, other ticketing partners including Alipay HK, Alipay, 01 Space and Octopus, or at convenience stores around Hong Kong. A single ticket grants access to all three events. The adult ticket price remains at HK$30. Children aged 0-3 and adults aged 65 or above are admitted free of charge. Visitors who enter before 12 noon and pay with their Octopus card enjoy a discounted entry fee of HK$10. The HKTDC also offers a re-entry promotion to those who purchase full-price tickets for the first two days. Physical ticket sales are not available on-site at the Book Fair – visitors can pay with AlipayHK, Alipay or Octopus at the entrance.

Hong Kong Book Fair, Hong Kong Sports and Leisure Expo and World of Snacks

Date	17-23 July 2024 (Wednesday to Tuesday)
Opening hours	Hong Kong Book Fair 17-22 July – 10am to 10pm 23 July – 9am to 5pm Hong Kong Sports and Leisure Expo and World of Snacks 17-18 July – 10am to 9pm 19-20 July – 10am to 10pm 21-22 July – 10am to 9pm 23 July – 9am to 5pm
Venue	Hong Kong Convention and Exhibition Centre
Admission	Adult: HK$30 Child: HK$10 (for primary school students/children under 1.2m tall) *Children aged 3 and under and adults aged 65 and over will be admitted free of charge.
Tickets	E-tickets are available for sale via the e-payment sponsor, the BoC Pay; and other ticketing partners, Alipay HK, Alipay, 01 Space and Octopus. Tickets are also available for sale at all 7-Eleven and Circle K stores and most of the ticketing platforms.
Concessionary tickets	Morning admission tickets (entry before noon, same price for adults and children): HK$10 (pay directly by Octopus for admission at the hall entrances only) Special re-entry promotion: Visitors who purchase a regular adult ticket (HK$30) or child ticket (HK$10) dated 17 or 18 July can enjoy free admission once in each of the following time slots by presenting the whole stub attached to the admission ticket or re-entry coupon distributed onsite: 1) 19-21 July (Friday to Sunday) after 7pm 2) 22 July (Monday) after 7pm Note: this offer is not applicable to other types of admission tickets (including morning admission tickets, concessionary tickets, VIP tickets and complimentary tickets) Super Pass: HK$88 Passholders have unlimited entry to the Book Fair and can use the special access channel to minimise queuing time.
Hong Kong Book Fair website and mobile app	www.hkbookfair.com hkbookfair.hktdc.com/HKBookfairApp.html (Check out the details of the book fair and register for the seminar)
Hong Kong Sports and Leisure Expo website	https://www.hktdc.com/event/hksportsleisureexpo/en
World of Snacks website	https://www.hktdc.com/event/worldofsnacks/en

Photo download: https://bit.ly/3y4lgPh

HKTDC’s Hong Kong Book Fair opens today. Together with the Sports and Leisure Expo and World of Snacks, the three summer events attracted 760 exhibitors.

Raistlin Lau, Under Secretary for Culture, Sports and Tourism of the HKSAR Government, was guest of honour at the Book Fair’s opening ceremony.

Raistlin Lau (front, second right), Under Secretary for Culture, Sports and Tourism of the HKSAR Government, Margaret Fong (front, second left), Executive Director of the HKTDC, and guests, including Cao Zhenya (front, far right), Deputy Director-General of The Publicity Department of the Central Committee of the CPC, and Zhai Degang (front, far left), Vice Minister of the Publicity Department of the Beijing Municipal Committee of the CPC, hosted the Book Fair opening ceremony.

In her remarks at this morning’s opening ceremony, Margaret Fong, Executive Director of the HKTDC, said that the Book Fair, an annual cultural event in Hong Kong in the summer, offers more than 600 cultural activities on-site and off-site, to promote literary exchange and connections and instil a joy of reading.

Book lovers eagerly await the opening of the Book Fair to get their hands on the latest literary works.

The World of Art & Culture presents literature in film and television from 31 countries and regions, with an interactive AI installation.

The Art Gallery showcases selected works from this year’s featured writers, attracting booklovers to appreciate their creativity.

The Sports Hub zone has introduced a new parent-child zipline experience, with participants invited to navigate through various obstacles before enjoying an exhilarating ride on a 15-metre-long zipline.

The Hong Kong Sports Institute has set up an instant photo booth, allowing the public to take pictures with props. These will be used to create a mosaic photo wall to show their support for Hong Kong athletes competing in the Olympics.

The perennially popular Japan Pavilion has expanded once again to reach its biggest scale since the pandemic. The Japan National Tourism Organization is teaming up with 18 Japanese prefectures to showcase the rich traditional culture of Japan

The World of Snacks has brought together more than 1,200 different snacks, to present visitors with a variety of classic flavours, healthy options and taste sensations from across the globe.

Disclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee.

Hong Kong Book Fair, Hong Kong Sports and Leisure Expo and World of Snacks
Yuan Tung Financial Relations:
Anson Wong Tel: (852) 3428 3413 Email: awong@yuantung.com.hk
Agnes Yiu Tel: (852) 3428 5690 Email: ayiu@yuantung.com.hk
Tiffany Leung Tel: (852) 3428 2361 Email: tleung@yuantung.com.hk

HKTDC’s Communications & Public Affairs Department:
Hong Kong Book Fair
Snowy Chan Tel: (852) 2584 4525 Email: snowy.sn.chan@hktdc.org
Sunny Ng Tel: (852) 2584 4357 Email: sunny.sl.ng@hktdc.org

Hong Kong Sports and Leisure Expo, World of Snacks
Jane Cheung Tel: (852) 2584 4137 Email: jane.mh.cheung@hktdc.org

HKTDC Media Room: http://mediaroom.hktdc.com

About HKTDC
The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.

China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG “AA” Rating

SHENZHEN, CHINA, July 16, 2024 – (ACN Newswire) – In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and continuous progress in sustainable development. CMS was reincluded in the 2024 Sustainability Yearbook (China Edition) issued by S&P Global, a global-leading corporate sustainability assessment institution, and maintained its “AA” rating in the updated MSCI (Morgan Stanley Capital International) ESG Rating Report.

Re-including in S&P Global’s Sustainability Yearbook (China Edition)

The S&P Global’s 2024 Sustainability Yearbook (China Edition) has been released. With an CSA score of 51 that surpassing 91% global peers in the industry, CMS stood out among more than 1,700 evaluated Chinese companies to be reincluded in the China Yearbook, becoming one of the five selected companies in the pharmaceutical industry.

Receiving “AA” once again in MSCI ESG Rating

In July, MSCI has released the latest ESG rating report for CMS. The Group has maintained “AA” rating, being positioned at the industry leading level globally.

CMS is committed to its ESG vision of “becoming a world-leading sustainable pharmaceutical enterprise,” continuously promoting the deep integration of sustainability concepts with its development strategy. The Group has established an ESG strategy covering various dimensions in operation, along with the Group’s mission and vision, and the expectations of stakeholders. Through a robust governance structure, CMS continuously strengthens ESG management and practices to facilitate the achievement of its ESG strategic goals.

Receiving high appraisal from two international authoritative organizations once again signifies the continuous recognition of the value and effectiveness of CMS’s sustainable development and relevant practice. In the future, CMS will continue to strengthen ESG governance and overall performance in corporate operations, social contributions, and environmental protection, and work together with all stakeholders to promote sustainable development and contribute to the realization of a green, healthy and prosperous future of human beings.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

CMS Disclaimer and Forward-Looking Statements

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Disclaimer Statement of MSCI

The use by China Medical System Holdings Ltd. of any MSCI ESG Research LLC or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of China Medical System Holdings Ltd. by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or service marks of MSCI.

Media Contact
China Medical System Holdings Ltd.
CMS Investor Relations
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

AIVF Set to Transform the IVF Process With AI Technology in the Australian Market

MELBOURNE, July 9, 2024 – (ACN Newswire) – AIVF, a leading innovator in fertility technology, is thrilled to announce that its cutting-edge AI-driven solutions are now available in the Australian market. This milestone brings the promise of enhanced fertility treatments and improved success rates to clinics and patients across Australia.

AIVF’s groundbreaking technology is designed to accelerate the time to pregnancy and increase predicted clinical pregnancy success rates, by leveraging advanced artificial intelligence. The inclusion in the Australian market ensures that patients now have access to some of the most sophisticated and well-tested fertility technologies available.

This achievement is the result of five years of intensive research, during which tens of thousands of embryos were analyzed using state-of-the-art AI models and data from five continents. This rigorous process underscores AIVF’s commitment to quality and excellence in reproductive health technologies.

“We are excited to bring our innovative solutions to Australia, marking a significant step forward in our mission to support individuals and couples on their journey to parenthood,” said Daniella Gilboa, CEO and Co-founder of AIVF. “Our technology is designed to provide a higher standard of care, improving clinical outcomes and optimizing the IVF process.”

AIVF’s platform enhances the IVF process through predictive analytics and decision support for all Relevant Health Professionals – such as a registered medical practitioner. This technology aims to improve success rates and optimize outcomes for fertility treatment patients, from early-stage embryo evaluation to genetic testing.

Clinics in Australia can now integrate AIVF’s solutions into their offerings, providing speedier, more accurate, and seamless IVF treatments. Patients will benefit from less invasive procedures, greater transparency, and higher success rates, ultimately leading to faster times to pregnancy.

This expansion marks a new era in IVF treatment, and AIVF invites clinics and patients across Australia to be part of this groundbreaking transformation.

For more information about AIVF and its innovative fertility solutions, please visit AIVF.co.

About AIVF

AIVF is at the forefront of fertility technology, dedicated to advancing reproductive health through artificial intelligence and data-driven solutions. Their mission is to support fertility clinics and their patients by providing innovative tools that enhance the IVF process and improve clinical outcomes.

Contact Information
Eyal Katz
VP Marketing
eyalk@aivf.co
+972542413730

SOURCE: AIVF

Perfect Medical Announces Annual Results for FY2023/24

RESULTS HIGHLIGHTS

The Group’s revenue amounted to HK$1,393.3 million, supported by the pickup in consumption momentum and the contribution from new shops in both Hong Kong and Mainland China.
The Group’s net profit slightly increased by 0.1% to HK$315.8 million, representing a net profit margin at 22.7%. Basic earnings per share were HK25.1 cents. Excluding the one-off government subsidies in the last financial year, the net profit increased by 6.8%.
The Group continues to maintain a strong financial position with bank and cash balance of HK$575.3 million without external bank borrowing.
The Board recommends the payment of a final dividend of HK11.9 cents per share and a special dividend of HK5.4 cents per share. Together with the interim dividend of HK13.2 cents per share and the special dividend of HK1.0 cent per share, the total dividend per share is expected to be HK31.5 cents per share for the full year, representing a total dividend payout ratio of 125.5%.
The Group’s total gross floor area now stands at 304,000 square feet.

HONG KONG, June 28, 2024 – (ACN Newswire) – Perfect Medical Health Management Limited (the “Company”, Stock Code: 1830.HK), one of the largest aesthetic medical operators in the world, together with its subsidiaries (collectively referred to as the “Group”), is pleased to announce its annual results for the year ended 31 March 2024.

For the year under review, the Group delivered a sustainable performance, supported by the pickup in consumption momentum and the contribution from new shops in both Hong Kong and Mainland China. The Group’s revenue increased by 0.3% to HK$1,393.3 million (FY2022/23: HK$1,389.3 million). Profit attributable to equity holders of the Company was HK$315.8 million, increased by 0.1% year-on-year (FY2022/23: HK$315.6 million), representing a net profit margin at 22.7% for the year (FY2022/23: 22.7%). Basic earnings per share were HK25.1 cents (FY2022/23: HK25.3 cents). As of 31 March 2024, the Group’s total gross floor area stands at 304,000 square feet.

Hong Kong Operation

Revenue from Hong Kong operation increased by 4.0% to HK$1,081.4 million (FY2022/23: HK$1,040.1 million), mainly attributable to the increasing customer patrons to the existing and new shops this year. Revenue from Hong Kong operation accounted for 77.6% (FY2022/23: 74.9%) of the Group’s revenue.

As of 31 March 2024, the Group had a well-established network of service centres in Hong Kong covering a total of 196,000 square feet. During the year, to enhance its store coverage and market share, the Group strategically added a total of eleven shops across different core areas in Hong Kong, including two flagship shops and nine residential shops.

The Group expanded its geographical footprint through a co-ordination between flagship and residential shops to add value to its customers and maintain agility in this evolving business landscape. This ecosystem seamlessly connects residential shops with flagship locations, resulting in overall consumption enhancement and new customers intake. The Group continued the residential shop expansion in the second half of the year, significantly bolstering its presence in Hong Kong.

To further diversify its non-aesthetic medical business, the Group forged a co-operation with a renowned Japanese brand, “Goku Spa”, in the Greater China region in January 2024, and launched “Goku Spa” sleeping therapy treatment outlets in Hong Kong during the year.

Regions outside Hong Kong

Revenue from regions outside Hong Kong was HK$311.9 million (FY2022/23: HK$349.2 million), supported by the positive revenue growth in Mainland China while impacted by the difficult environment in both Australia and Singapore. Currently, revenue from the regions outside Hong Kong accounted for 22.4% of the Group’s revenue (FY2022/23: 25.1%).

As of 31 March 2024, the Group has an extensive network of service centres in regions outside Hong Kong covering a total service area of 108,000 square feet.

For the year under review, revenue from Mainland China and Macau increased year-on-year, mainly benefiting from post-pandemic consumption recovery and contributions from new shops. For the year ended 31 March 2024, the Group redeployed a total of four new shops in Shenzhen and Shanghai. The performance of Australia and Singapore has been significantly affected by the persistent inflation pressures and wage increases, which also impacted the Group’s overall financial performance.

Prospects

Dr. Au-Yeung Kong, the executive director, chairman and chief executive officer of Perfect Medical, said that “the macroeconomic situation remains challenging. It is expected that both Hong Kong and Mainland China’s economy will maintain its recovery momentum, supported by the continual improvement in domestic spending and the governments’ stimulus measures.

We will continue to pursue the ‘Dual-Circulation’ strategy via the combination of aesthetic and non-aesthetic medical services, in order to navigate the present headwind and further promote the growth and profitability of Perfect Medical. Additionally, the Group is diversifying into non-aesthetic medical services, and establishing alliances with different international providers — a strategic move set to strengthen our frontier position in Hong Kong.

For the expansion in Mainland China, the Group is selectively expanding its presence in key economic regions like the Greater Bay Area and Eastern China. This measured expansion allows the Group to capitalise on viable opportunities while ensuring sustainable, long-term value creation for the investors and stakeholders. We are dedicated to fostering a sustainable business model that not only meets our economic objectives but also makes a positive impact on society.”

For further information of the Group’s FY2023/24 annual results, please refer to the Company’s Annual Results Announcement on the Hong Kong Stock Exchange website at: https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0628/2024062800644.pdf

About Perfect Medical Health Management Limited

Perfect Medical Health Management Limited is a multinational aesthetic medical corporate and one of the largest aesthetic medical operators in the world established in 2003. The Group focuses primarily on non-invasive aesthetic medical services and medical services in Hong Kong, China, Macau, Australia and Singapore with a total service area spanning approximately 304,000 square feet as of 31 March 2024. Its operation offers a broad spectrum of professional services with assurance of utmost safety and efficacy. The Company has been included as a constituent stock of the MSCI Hong Kong Micro Cap Index, demonstrating the confidence from the capital market and recognising the investment value of the Company.

For further information, please contact:

Perfect Medical Health Management Limited	iPR Ogilvy Limited
Marco So / Peter Kwok Email: ir@perfectmedical.com Tel: (852) 2770 2099	Callis Lau / Tina Law / Rita Chen Email: perfectmedical@iprogilvy.com Tel: (852) 2136 6185

CGFNS International Announces First Global Credential for Rehab Nurses

PHILADELPHIA, PA, June 28, 2024 – (ACN Newswire) – CGFNS International, a worldwide leader in international credentials evaluation to support health worker careers, has launched the first-ever global credential for registered nurses working in rehabilitation, habilitation or restorative care.

CGFNS Certified Global Nurse – Rehabilitation

The Certified Global Nurse – Rehabilitation (CGN-R) credential is intended to advance and improve services for the more than two billion people worldwide who need this care. It has been developed specifically for eligible registered nurses worldwide who wish to have their applied experience and competencies in rehab care recognized and verified by passing a certification examination.

The exam was created in collaboration with a global task force of more than 60 rehabilitation nursing experts from 17 countries who contributed their knowledge and guidance to develop a global competency framework for rehabilitation nursing and to create a test blueprint for a competency-based exam. The task force’s framework is aligned with the Rehabilitation Competency Framework established by the World Health Organization.

Accordingly, those who earn the CGN-R credential will be able to show their employers, prospective employers and others that they have been assessed against a global industry standard for rehabilitation care and that their expertise has been benchmarked against other nurses in rehab care worldwide.

Registration for the CGN-R exam will open in July, with testing dates to be scheduled for November. Registered (first-level) nurses with at least two years’ work experience in rehabilitation care are eligible to apply. Further details on eligibility requirements, exam topics and how to apply can be found in the exam handbook, now available at the CGFNS website.

“This will be the first global specialty certification offered anywhere for rehab nursing. It represents a huge shift for our global health workforce, for whom specialty credentials are often out of reach and require migration to the countries that offer them. The CGN-R certification will enable rehabilitation nurses everywhere to demonstrate a validated specialty skillset to their employers, carry the credential with them wherever they want to work in the world, and advance their career opportunities,” said Julia To Dutka, Chief of the CGFNS Global Health Workforce Development Institute, which is leading the initiative to develop this and other global credentials for the rehabilitation workforce.

“Provider certifications enable health systems and hospitals to confidently identify the most well-equipped workforce candidates to meet their burgeoning care needs. At a time when qualified interdisciplinary care teams are critically needed in rehabilitation care, the CGN-R establishes a global standard against which employers can set the bar for provider qualifications within their health systems,” said Terrence Carolan, Managing Director of Medical Rehabilitation and Aging Services of CARF International, an independent, nonprofit organization that accredits more than 66,000 rehabilitation and other health and human service providers on five continents and that has advised CGFNS in developing the CGN-R credential.

Nurses who sit for the initial CGN-R exam in November will receive a discount on exam fees.

CGFNS is also offering an early adopter program for hospitals, health systems or rehabilitation organizations that would like to invest in specialty certification for their rehab nurse workforce. The program includes opportunities to host the CGN-R exam onsite for their rehab nursing teams and earn an early adopter’s badge for organizational recognition.

Information on additional credentials for other health workers in a rehabilitative/habilitative/restorative environment – including physical and occupational therapists, speech-language pathologists and rehab technicians, among others – will be made available in the coming months.

More information on the program can be found at https://www.cgfns.org/services/certification/global-rehabilitation/

About CGFNS International, Inc.

Founded in 1977 and based in Philadelphia, CGFNS International is an immigration-neutral not-for-profit organization proudly serving as the world’s largest credentials evaluation organization for the nursing and allied health professions. CGFNS International is an NGO in Consultative Status with the United Nations Economic and Social Council (ECOSOC) and is a member of the Conference of NGOs in Consultative Relationship with the United Nations (CoNGO).

Contact Information
David St. John
dstjohn@cgfns.org

SOURCE: CGFNS International

China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China

SHENZHEN, June 25, 2024 – (ACN Newswire) – On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China. This is another substantial clinical development milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo.

This trial is a randomized, double-blind, placebo-controlled phase III clinical trial evaluating the efficacy and safety of ruxolitinib cream in the treatment of atopic dermatitis in Chinese patients. The trial aims to provide more medical evidence to support the Product’s marketing application in China. The trial, led by Professor Shi Yuling, Vice President of Shanghai Skin Disease Hospital, will be conducted in 20 sites nationwide aiming to enroll approximately 192 atopic dermatitis patients.

AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there are approximately 26 million[1] AD patients in China, of whom about 23 million[2] are mild to moderate. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) have long-term adverse reactions or limited efficacy[3] [4], therefore novel treatments are urgently needed, especially for those mild to moderate AD patients who do not need systemic treatment.

About ruxolitinib cream

Ruxolitinib cream (Opzelura®), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, and is the first and only treatment for repigmentation approved for use in the United States[5]. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[6]. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[7].

Ruxolitinib cream is not approved by the National Medical Products Administration of China (NMPA) for any indication in Mainland of China. However, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”) on 18 August, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. The Group is cooperating with Boao Super Hospital to conduct the Real World Research (RWS) for the Product, which could support the registration and launching of the Product in Mainland of China.

Moreover, the Pharmaceutical Administration Bureau (ISAF) of Macau has approved the new drug application of ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age on 11 April 2024, and it may bring a novel therapeutic option to patients with relevant indication in the area.

Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. CMS has an exclusive license to develop and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory.

Opzelura and the Opzelura logo are registered trademarks of Incyte.

CMS continues to pay close attention to patients’ needs, and actively promotes the R&D and clinical application of innovative products to address unmet clinical needs, bringing more quality medical products to patients through differentiated innovation breakthroughs.

About CMS

Reference:

1. M.R. Laughter, M.B.C. Maymone, S. Mashayekhi, B.W.M. Arents, C. Karimkhani, S.M. Langan, R.P. Dellavalle, C. Flohr, The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017, British Journal of Dermatology, Volume 184, Issue 2, 1 February 2021, Pages 304–309, https://doi.org/10.1111/bjd.19580

2. Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, Grayson MH, Margolis DJ, Mitchell L, Silverberg JI, Schwartz L, Simpson EL, Ong PY. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. J Invest Dermatol. 2019 Mar;139(3):583-590. doi: 10.1016/j.jid.2018.08.028. Epub 2018 Oct 30. PMID: 30389491

3. “Research Report on the Living Conditions of Atopic Dermatitis Patients in China” August 2020

4. Yimi Survey “Atopic Dermatitis Diagnosis and Cognition Survey” October 2023

5. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older

6. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream

7. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

Media Contact
China Medical System Holdings Ltd.
CMS Investor Relations
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

[Media Alert] Are You ‘Man’ Enough to Embrace Your Inner Health?

SINGAPORE, June 25, 2024 – (ACN Newswire) – Today, an increasing number of men are prioritising their health and well-being, a shift significantly accelerated by the onset of the COVID-19 pandemic. This change in mindset has led to a burgeoning interest among men in various aspects of health, from physical fitness and mental well-being to nutritional supplementation, skin and beauty care and preventative care.

The impact of this shift is evident in the market dynamics with the global men’s health supplement market, which was valued at $67.49 billion in 2022 projected to grow substantially, reaching an estimated $109.25 billion by 2027. This growth is largely driven by several factors, including heightened awareness of health issues, the proliferation of health information accessible through digital platforms, and a cultural shift towards self-care and longevity among men.

Moreover, the rise of personalised health regimes and the availability of targeted health supplements specifically designed for men are playing a crucial role in this market expansion. Men are increasingly seeking products that address specific health concerns such as cardiovascular health, prostate health, muscle growth, and mental clarity.

To commemorate International Men’s Health Week from June 10 to 16, LAC (pronounced L-A-C) is dedicated to highlighting the importance of men’s health. During this week, we aim to provide valuable tips and advice on how men can enhance their overall well-being and embrace their inner health.

An apple a day is not enough to keep the doctors away

Men are nearly three times more likely than women to consume fast food on a daily basis. Despite this, many men lead active lifestyles, frequently hitting the gym or engaging in physical activities to enhance their health and fitness. Given these dynamics, it is more crucial than ever for men to ensure they consume sufficient nutrients and minerals to support their active lives. Incorporating a multivitamin into their daily routine can help bridge this nutritional gap.

LAC Men’s Mega Multi Active and LAC Men’s Mega Multi 50 Plus offer comprehensive solutions with formulas containing over 40 clinically researched vitamins and minerals. These supplements not only help to enhance overall health, immunity, metabolism, and vitality, but also contribute towards boosting energy levels, promoting faster recovery times, and improving athletic performance. They serve as an ideal all-in-one supplement solution for men with busy lifestyles, ensuring they receive the essential nutrients needed to maintain their health and optimise their physical performance.

Recognise the importance of caring for your prostate and bladder

Your prostate gland plays a crucial role in your reproductive anatomy and sexual health. Regardless of age, all men are at risk of developing prostate problems if proper care is not taken. Neglecting prostate health can lead to negative effects such as urinary issues.

Incorporating supplements that are specifically targeted towards promoting prostate and bladder health such as LAC Men’s ProstAid Formula and LAC Men’s UI Formula can be beneficial towards a healthy prostate and bladder. Formulated with clinically-studied ingredients such as saw palmetto and beta-sitosterol, LAC Men’s ProstAid Formula promotes prostate health and supports proper prostate function and when paired with LAC Men’s UI Formula, which includes key ingredients like copper and lycopene, these supplements work together to protect your prostate, improve testosterone health and enhance overall reproductive vitality.

As men increasingly prioritise their overall health and well-being, it is essential for us to recognise that your inner health deserves as much if not more attention than external factors such as exercises and skincare.

Media Contact: lac@preciouscomms.com

HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)

ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024 – (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association’s (ADA) 84th Scientific Sessions, taking place from June 21-24, 2024 in Orlando, Florida. The presentation is a post-hoc analysis of the Phase 2 clinical study of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with type 2 diabetes mellitus (T2DM) (NCT06411275).

Based on the successful Phase 2 study, two Phase 3 studies (NCT06350890, NCT06353347) are currently ongoing to further evaluate the efficacy and safety of HTD1801 (as monotherapy and as add-on to metformin) in patients with T2DM and inadequate control. “We look forward to the results of our pivotal T2DM program which we expect to announce in the first half of 2025,” said Dr. Leigh MacConell, Chief Development Officer of HighTide.

“Berberine Ursodeoxycholate (HTD1801) Improves Key Glycemic and Cardiometabolic Parameters Across the T2DM Disease Spectrum” (Abstract 847-P, Poster Presented June 23rd)

About the Abstract:

In a Phase 2, placebo-controlled, double-blind study in patients with T2DM, treatment with HTD1801 for 12 weeks resulted in significant dose-dependent improvements in key glycemic parameters. The objective of this post-hoc analysis was to evaluate the effectiveness of HTD1801 in patients with T2DM across the disease spectrum based on baseline HbA1c, with a particular emphasis on glycemic and lipid metabolism markers, along with indicators of liver injury. These data show that regardless of baseline disease severity, HTD1801 treatment resulted in significant improvements across these key parameters. The magnitude of improvement was greater in those with more severe disease. HTD1801 may offer a unique therapeutic approach for individuals with T2DM and other comorbidities (i.e. MASH and dyslipidemia), as managing these conditions effectively is crucial in controlling T2DM and reducing its associated complications.

About HighTide Therapeutics

HighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Disclaimer

The information contained herein is based solely on events or data available as of the date of this document. Unless required by law, we are under no obligation to update or publicly revise any forward-looking statements or events beyond those anticipated, even if new information, future events, or other circumstances arise after the date of the forward-looking statement. Please review this document carefully and be aware that our actual future performance or results may significantly deviate from expectations. All statements in this document are made as of the publication date and may change considering future developments.

For more information, please visit www.hightidetx.com

Contact: pr@hightidetx.com

JBM Healthcare Announces FY2024 Annual Results

KEY HIGHLIGHTS

Year-on-year revenue increased by 24.6%, totalling HK$648.4 million
Adjusted profit attributable to equity shareholders* soared 149.5% to HK$130.5 million
The Board recommends a final dividend of HK4.05 cents per share
All three business segments exhibited robust growth momentum
Flagship proprietary brands Ho Chai Kung and Po Chai Pills led with impressive growth
Cross-border e-commerce continued to grow on various platforms

HONG KONG, June 18, 2024 – (ACN Newswire) – JBM (Healthcare) Limited (“JBM Healthcare” or the “Company”; Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2024 (“FY2024” or the “Reporting Period”).

During the Reporting Period, the Group’s branded healthcare business achieved a 24.6% increase in revenue, totaling HK$648.4 million. Gross profit for the same period rose by 64.5% to HK$338.1 million. Adjusted profit attributable to equity shareholders* surged by 149.5% to HK$130.5 million. This robust performance is primarily due to improved retail market sentiment and successful marketing strategies for key brands in the proprietary medicine category, notably Ho Chai Kung and Po Chai Pills.

The Board recommends a final dividend of HK4.05 cents per share. Including the interim dividend of HK3.45 cents per share already paid, the total dividend for FY2024 will be HK7.5 cents per share.

Effective Brand Management Fueled Robust Performance

In the branded medicines business, sales revenue achieved a significant growth of 53.3%, primarily attributable to the remarkable performance of Ho Chai Kung products. A widely recognised household name for over-the-counter painkillers and fever relief, Ho Chai Kung has experienced a significant boost in sales, which is attributed to its effective brand marketing strategy alongside effective sales channel management. The brand’s launch of a new TV advertising campaign featuring celebrity Hins Cheung, has received a tremendous response from the audience. The creative campaign, “Trust Hin Gong, Use Ho Chai Kung”, garnered substantial views and likes across various social media platforms, creating a trending topic in the city and significantly enhancing the brand’s visibility in Hong Kong.

The proprietary Chinese medicines segment exhibited an overall 7.3% increase in revenue, fueled by the strong growth of Po Chai Pills and the sustained momentum of the Group’s concentrated Chinese medicine granules business. During the Reporting Period, Po Chai Pills successfully launched a new TV advertisement named “Ivana’s Po Chai Pills Digestive Tune” targeting a younger audience and reinforcing its leadership in Chinese gastrointestinal medicine. Renowned singer-song writer Ivana Wong lends her voice to a revamped version of the classic jingle, “Take Po Chai Pills for Rapid Relief”, which resonates with viewers, invokes nostalgic memories and revitalises the brand.

Sustained Development in Cross-Border E-commerce

The Group’s cross-border e-commerce division continued its growth trajectory and remained a consistent contributor to the Group’s profits. This was driven by strong demand for its proprietary brands, such as Ho Chai Kung and Po Chia Pills, as well as solid performances in the medical devices and beauty products segments. In the fourth quarter of 2023, the Group launched its Tmall Ho Chai Kung Overseas Flagship Store, intending to bolster the brand’s image and recognition while expanding its consumer base in Mainland China.

Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, commented, “In FY2024, JBM Healthcare capitalised on promising growth opportunities amid the notable rebound of Hong Kong’s retail sector, leveraging our strategic acumen and robust execution.”

“As we forge ahead, we are poised to harness transformative trends in healthcare. We will prioritise operational excellence, productivity, and shareholder value while enhancing efficiency and actively expanding its sales platforms and geographic reach. By providing trusted, branded healthcare products, JBM Healthcare empowers consumers to better manage their health, aligning with its mission.”

About JBM (Healthcare) Limited (Stock Code: 2161)

JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers’ healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, Mederma for Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk

China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China

Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint).
The Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits.
As of now, CMS’s newly launched innovative portfolio has been expanded to 5 products, continuously generating driving force to the Group’s sustainable and healthy development.

SHENZHEN, June 18, 2024 – (ACN Newswire) – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 11 June 2024, the New Drug Application (NDA) of the Group’s innovative drug methylthioninium chloride enteric-coated sustained-release tablets (Lumeblue®) (the “Product”) has been approved by the National Medical Products Administration of China (NMPA). The drug registration certificate was obtained on 18 June 2024. The Product is indicated to enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy, and it is the first oral methylthioninium chloride enteric-coated sustained-release tablets in China. The Group will synergize with existing gastroenterology products and resources to advance the commercialization and academic promotion related works of the Product in an orderly manner, aiming to achieve nationwide large-scale clinical application as soon as possible so as to benefit patients with colorectal disease.

Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMX) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits.

According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Chinese consensus of early colorectal cancer screening recommends that people aged 50 to 75 years old should be screened for colorectal cancer regardless of whether they have alarm symptoms[3]. There are approximately 400 million people aged 50 to 75 in China in 2020[4]. With the popularity of early screening for colorectal cancer in China, it is expected to witness a considerable growth of the number of colonoscopies in China in the future.

The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue™ in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd, a fully owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020.

Driven by the twin-wheel of “Collaborative R&D and Independent R&D”, CMS has continuously deployed global first-in-class (FIC) and best-in-class (BIC) innovative products guided by patient and clinical demands. With enhancing R&D capabilities in developing differentiated innovative products, CMS has empowered the continuous transformation of scientific research outcomes into clinical application, continuously releasing the value of innovation. As of now, CMS’s newly launched innovative portfolio has been expanded to 5 products, continuously generating driving force to the Group’s sustainable and healthy development. Desidustat Tablets and Methotrexate Injection (rheumatoid arthritis), CMS’s innovative pipeline products, are currently under NDA review in China. Meanwhile, over 10 innovative pipeline products are undergoing clinical trials in China, mainly randomized controlled trials (RCT). CMS is expected to launch differentiated innovative products every year in the future with higher efficiency and more controllable costs, continuing to optimize its product portfolio and build fresh driving forces for the mid- to long-term development of the Company.

About CMS

Reference:

1. The results of the Phase III clinical trial in China was published and can be found at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-clinical-trial-of-methylthioninium-chloride-enteric-coated-sustained-release-tablets/

2. The diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association

3. Chinese consensus of early colorectal cancer screening (2019, Shanghai)ï¼ŒChinese Journal of Internal Medicineï¼ŒDOIï¼š 10.3760/cma.j.issn.0578-1426.2019.10.004

4. CHINA POPULATION CENSUS YEARBOOK 2020, can be found atï¼š https://www.stats.gov.cn/sj/pcsj/rkpc/7rp/zk/indexch.htm

CMS Disclaimer and Forward-Looking Statements

Media Contact
China Medical System Holdings Ltd.
CMS Investor Relations
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.